2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Transplantation, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Thromboembolism, Bone Marrow Failure Syndromes, Genetic Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, MDS, MPN, CML, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2843 Real-world hemoglobin response and duration of anemia response in patients with myelofibrosis treated with pacritinib

Ashwin Kishtagari, MBBS, MSCI, Stephen Oh, MD, PhD2, Michael Marrone, PhD, MPH3, Bryce Allen-Van Doren, PhD4, Camryn Craig5, Purvi Suthar6, Abiola Oladapo, PhD7, Michael Vredenburg, PhD8, Andrew T Kuykendall, MD9
1 Vanderbilt University Medical Center, Nashville, Tennessee, United States
2 Washington University School of Medicine, St. Louis, Missouri, United States
3 Sobi Inc., Waltham, Massachusetts, United States
4 Cardinal Health, Dublin, Ohio, United States
5 Cardinal Health, Dublin, Ohio, United States
6 Sobi Inc., Waltham, Massachusetts, United States
7 Sobi Inc., Waltham, Massachusetts, United States
8 Sobi Inc., Waltham, Massachusetts, United States
9 Moffit Cancer Center, Tampa, Florida, United States
Anemia is a major clinical burden in myelofibrosis (MF) associated with poor prognosis. Pacritinib (PAC), a JAK1-sparing inhibitor of JAK2/IRAK1/ACVR1, can be delivered at full dose regardless of cytopenias and has demonstrated hematological benefit in clinical trials (e.g., PERSIST-2, NCT02055781). Real-world evidence on Hb response and response durability with PAC remains limited. We evaluated these outcomes in a real-world cohort of patients with MF treated with PAC.

Data from EMOL Health, a community oncology electronic medical record data-aggregation platform, were used to identify pts with MF treated with PAC for ≥1 month between June 2022 and September 2025 with ≥6 months of follow-up from PAC initiation (index), unless death occurred earlier. Pts were evaluable for anemia response if they had Hb<10 g/dL at index, pre-index RBC transfusion data, and Hb and transfusion data while on PAC. At index, pts were classified per 2024 IWG-ELN criteria as transfusion-dependent anemia (TDA; ≥3 RBC units in the prior 12 weeks and most recent transfusion ≤28 days before index) or non-TDA (did not meet TDA criteria). Severe bicytopenia was defined as Hb<8 g/dL and platelet (PLT) count <50×10⁹/L at index. IWG-ELN 2024 Hb response was assessed hierarchically as best overall response, with major and minor responses mutually exclusive. For TDA, major response required a ≥1.5g/dL rolling 12-week average Hb increase and transfusion independence; minor response required a ≥50% reduction in transfusion burden. For non-TDA, major and minor responses required ≥1.5 and ≥1.0g/dL rolling 12-week average Hb increases, respectively, without transfusions. Duration of PAC treatment, anemia response, and OS were estimated using Kaplan-Meier (KM) methods.

Among 48 PAC-treated pts with Hb<10 g/dL at index, the median age was 77.0 years (Q1-Q3: 69.6-81.1), and 52.1% (25/48) were male. Most pts received PAC as their second JAK inhibitor (31/48, 64.6%), with a median interval of 23.3 months from MF diagnosis to PAC initiation. Among pts receiving PAC after a prior JAK inhibitor, ruxolitinib was the most common prior therapy (23/31, 74.2%), followed by fedratinib (7/31, 22.6%) and momelotinib (1/31, 3.2%). Most pts initiated PAC at a total daily dose of 400mg (35/48, 72.9%). At index, median Hb was 8.5g/dL (Q1-Q3: 7.7-9.3) and median PLT count was 50×10⁹/L (Q1-Q3: 28-122); 32 pts (66.7%) had severe bicytopenia at treatment initiation. The median follow-up duration from PAC initiation was 8.4 months (Q1-Q3: 6.0-18.2); the KM-estimated median duration of PAC treatment was 7.7 months (95% CI: 4.1-10.5). 

Of the 46 pts evaluable for Hb response, 10 (21.7%) were TDA and 36 (78.3%) were non-TDA at index.  During treatment, 19 pts (41.3%) achieved an IWG-ELN 2024 Hb response, including 15 (32.6%) major and 4 (8.7%) minor responses. Among pts with TDA at index, 3/10 (30.0%) achieved a major response and 3/10 (30.0%) achieved a minor response. Among pts with non-TDA at index, 12/36 (33.3%) achieved a major response and 1/36 (2.8%) achieved a minor response.  Among IWG-ELN 2024 responders, the median Hb increase during the response-defining period was 2.1g/dL (Q1-Q3: 1.3-2.8) in pts with TDA at index (n=6) and 1.6g/dL (Q1-Q3: 1.6-1.7) in those with non-TDA at index (n=13). Overall, 78.9% (15/19) of responders achieved an Hb level ≥10.0 g/dL during treatment. PLT counts remained stable throughout follow-up, with median PLT counts of 63 (Q1-Q3: 35-146), 67 (Q1-Q3: 31-135), 72 (Q1-Q3: 29-125), and 73×10⁹/L (Q1-Q3: 41-134) at Days 30, 60, 90, and 180, respectively. The KM-estimated median duration of major or minor anemia response was 42.7 weeks overall (95% CI: 18.0-58.7; TDA responders: 27.6 weeks (95% CI: 11.9-NE) non-TDA responders: 58.7 weeks (95% CI: 14.0-NE)). The median KM-estimated OS was 21.8 months (95% CI: 12.2-NE), and the KM-estimated 6-month survival probability was 75.0% (95% CI: 60.2-85.0).

In this real-world cohort, PAC was associated with Hb improvement in a substantial proportion of pts with MF-associated anemia and severe cytopenias, in both TDA and non-TDA subgroups. The clinically meaningful and durable Hb responses in both TDA and non-TDA pts points to PAC’s potential for treatment of MF-associated anemia. These findings extend prior real-world observations of PAC by demonstrating durable anemia responses using IWG-ELN 2024 response criteria in an independent, curated data source.

Ashwin Kishtagari, MBBS, MSCI: Geron Corporation - Current equity holder in publicly-traded company; Syndax - Current equity holder in publicly-traded company; Syndax - Current equity holder in private company; Servier Pharmaceuticals - Consultancy (Includes expert testimony)